Yamo Pharmaceuticals

09/23/2025

We applaud 's efforts to address the ongoing crisis. We’re thankful for the designation granted to Yamo’s L1-79. After positive , looks forward to ’s support as it works to bring to

05/02/2025

TODAY @ 6:06 PM PST INSAR 2025... Our very own Dr. Tom Megerian is giving 1 of just 3 ORAL PRESENTATIONS during INSAR Session 327 Clinical Trials Dietary and Small Molecule Treatments!

Our CMO will finally be presenting our recent clinical trial results! L1-79 is an investigational new drug. We are excited to share our possible steps toward greater ASD support with you. 🎉

04/30/2025

First Day of INSAR 2025! Stay tuned for an oral presentation on our Phase 2 Clinical Trial results by Chief Medical Officer Dr. Tom Megerian on DAY 3 of the International Society for Autism Research Conference in Seattle.

We are thrilled to have two of our team members, Chief Medical Officer Dr. Tom Megerian and Senior VP Dr. Tracy Fischer represent Yamo Pharma at this prestigious conference.

04/28/2025

What does the increase in prevalence of ASD diagnoses mean to us? It's simple. More families and more individuals need support.

People may disagree on the cause of Autism, or why numbers are increasing, but one thing is for sure-- every diagnosis represents a real person, a real family, and a real need for understanding, resources, and community. Our responsibility is not to debate the numbers, but to meet the growing need with compassion, action, and commitment. That's why we're here.

04/28/2025

04/15/2025

L1-79 is an innovative therapeutic designed to address core symptoms of autism-- particularly challenges related to socialization.

L1-79 works by modulating the catecholamine pathways, which influence critical brain functions such as mood, attention, motor skills, and social behavior.

In recent clinical trial Phase 2b, L1-79 showed the potential to improve effects of socialization-related challenges as well as the three most bothersome symptoms identified by caregivers, with no serious safety concerns noted. L1-79 is an investigational new drug.

It will not be a cure – but it may represent a new opportunity for those seeking meaningful support.

04/15/2025

Only members of the Autism community know: there are currently NO FDA approved drugs for the CORE symptoms of autism.

We are developing L1-79, investigational new drug, to change that.

03/31/2025

We are Yamo. We’re here to raise awareness about our mission:

to improve the quality of life for individuals with autism by developing L1-79, a first-in-class treatment targeting core ASD symptoms including challenges in socialization. L1-79 is an investigational new drug.

This isn’t about changing who someone is. It’s about opening doors—to connection, to greater independence, and to possibility.

Follow along as we share our journey to reach Phase 3 Clinical Trials.